Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study

By afschroeder • October 9, 2025

Papp KA, Jacobs S, Sofen H, Bukhalo M, Muscianisi E, Ma G, Lau G, Bettinger M, Rubio RG, Hitraya E, Blauvelt A; Open-Label Extension study team. Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study. J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02952-4. doi: 10.1016/j.jaad.2025.10.005. Epub ahead of print. PMID: 41061968.

Tags: Dermatology, durability, efficacy, envudeucitinib, ESK-001, long-term extension, Olive View DoM, phase 2, plaque psoriasis, Publications, safety, STRIDE, TYK2

Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease: A National Cohort Study of the MarketScan Databases

Cortes JA, Nong Y, Smart K, Aflatooni S, Palma G, Johnsen N, Ure A, Armstrong AW. Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease:[...]

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis

Armstrong AW, Burne R, Bin Sawad A, Lemyre A, Gauthier-Loiselle M, Guerin A, Vinson T, Milovac B, Balu S. Treatment Patterns and Economic Burden in[...]

DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes

Hsu FM, Pickering H, Bosinger SE, Eckalbar W, Maecker HT, Kim-Schulze S, Ozonoff A, Diray-Arce J, Schaenman JM, Reed EF, Pellegrini M. DNA methylation profiles[...]